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Background: Body weight loss is an important feature of heart failure (HF) and tumors. 
It is related to both reduced survival and adverse reactions to therapy in both of these 
conditions. The mechanisms of body weight loss in patients with HF and tumors are 
considered to be similar. Yet, studies comparing those two populations are generally 
lacking. The aim of this study was to compare anthropometric and laboratory data, 
related to weight loss, between patients with chronic HF and patients with different 
tumors as well as control population.
Methods: Laboratory and anthropometric data on 143 consecutive patients with chronic 
HF and malignant diseases as well as data for 20 controls were collected.
results: Patients with HF had lower levels of C-reactive protein (CRP) and albumin 
compared to controls. Anthropometric measurements revealed lower body mass index 
(BMI), muscle strength, mid-arm circumference, and waist circumference in patients with 
HF compared to controls. Measurements of biceps, triceps, subscapular, and suprailiac 
skinfolds were also lower in HF group. Compared to solid tumor group, HF patients had 
lower levels of CRP and higher levels of hemoglobin. Solid tumor patients had lower 
values of BMI and subscapular skinfold thickness, as well as higher muscle strength 
compared to HF group. Finally, compared to patients with solid hematological tumors, 
HF group had lower levels of albumin, lower muscle strength, as well as lower mid-arm 
circumference.
conclusion: We found differences in anthropometric and laboratory features, related 
to weight loss, in patients with HF compared to control population that were expected. 
On the other hand, observed differences in HF group compared to patients with various 
tumors could imply different pathophysiological mechanisms of weight loss between 
those groups. Such data could serve as a cornerstone for studies with larger numbers 
of patients and deeper pathophysiological insight.
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inTrODUcTiOn
Weight loss is a common finding in patients with chronic heart 
failure (HF) and tumors, as well as in other chronic diseases. 
Significant weight loss, usually defined as cachexia, affects 
approximately five million people in the United States of America 
annually (1) and results in two million deaths (2). It is also related 
to adverse reactions to various therapeutic modalities (3, 4).
Pathophysiological mechanisms responsible for weight loss 
in chronic HF and tumors are regarded similar (5, 6). The same 
mechanisms responsible for weight loss are responsible for some 
important laboratory and anthropometric features that can be 
found in patients suffering from chronic HF or tumor diseases. 
Several studies have found important differences in anthropo-
metric measurements between patients with chronic HF (7) or 
tumors (8) and control population. Differences in several labora-
tory parameters were also found. Among them C-reactive protein 
(CRP), hemoglobin, and albumin are best studied. Their values 
were, therefore, incorporated in the recent definitions of the most 
pronounced form of weight loss called cachexia (6, 9). To date, 
there are no studies that compared anthropometric and labora-
tory features of patients with chronic HF and tumor diseases.
Principal aim of our study was to investigate possible dif-
ferences in anthropometric and laboratory features, related to 
weight loss, in patients with chronic HF compared to patients 
with various tumors and control population. We gathered clini-
cal data from 143 consecutive patients with malignant diseases 
or chronic HF hospitalized in a single institution. Patients with 
malignant diseases were further subdivided into group suffering 
from solid tumors and a group with hematological malignancies. 
We also gathered same data for 20 controls. We then compared 
anthropometric and laboratory findings of patients with chronic 
HF with patients in both tumor groups and with control group.
PaTienTs anD MeThODs
Patients
The study was conducted at the Department of Internal Medicine 
of University Hospital Merkur in Zagreb. Data were collected 
from May 2011 until May 2012 in consecutive patients who 
were eligible for entry. A diagnosis of either solid hematological 
tumors (non-Hodgkin lymphoma, Hodgkin disease), other solid 
tumors of any site, or chronic HF of any etiology was mandatory. 
Diagnosis of malignant disease had to be proven with adequate 
histopathological sample. Diagnosis of HF was made according 
to the guidelines criteria (10). Control population consisted of 
persons without proven malignancy or chronic HF.
Exclusion criteria were: age less than 18  years, starvation 
defined as deliberate or unintentional reduced food consumption 
despite preserved appetite, malabsorption defined as documented 
or suspected disease related to malabsorption, diarrhea defined 
as having three or more loose or liquid stools per day or as hav-
ing more stools than is normal for a given patient, active thyroid 
disease, depression or other severe psychiatric disease, chronic 
obstructive pulmonary disease, chronic kidney disease stage ≥3, 
myocardial infarction in less than last 12 weeks, liver insufficiency 
defined by clinical or laboratory signs of its synthetic or metabolic 
dysfunction or a documented cirrhosis, neuromuscular diseases, 
and alcohol or drug abuse.
The study received previous local ethical board approval and 
was conducted according to the Declaration of Helsinki and its 
subsequent amendments. All patients gave written informed 
consent before participation in the study.
evaluation of Patients
Complete history and full physical examinations were per-
formed at baseline. Baseline blood analyses included complete 
blood count and complete biochemistry (including values of 
hemoglobin, CRP, and albumin). All measurements were done 
according to the protocol of institutional laboratory.
Anthropometric measurements were done as follows. Muscle 
strength was obtained using handgrip dynamometer. Three con-
secutive measurements at least 5 s apart were done. Highest of the 
measurements was used for analysis. Measurements of skinfolds 
(biceps, triceps, subscapular, and suprailiac) and circumferences 
(mid-arm, waist, and hip) were done using previously published 
protocols (7). All measurements were done three times at each 
site. Calculated mean value was used for analysis. Body mass 
index (BMI) was calculated as weight in kilograms divided with 
squared height in meters.
statistics
The results were expressed as the mean ± SD or as a proportion 
of the total number. Mann–Whitney test was used to test the 
equality of continuous variables. A p-value < 0.05 was consid-
ered statistically significant. All statistics were performed with 
the StatView™ statistical program, version 5.0.1 (SAS Institute, 
Cary, NC, USA).
resUlTs
Baseline clinical characteristics  
of Patients
One hundred forty three (86 males) consecutive patients and 20 
(11 males) controls were enrolled. Chronic HF was diagnosed 
in 45 patients (33 had ischemic cardiomyopathy, 7 had dilated 
cardiomyopathy, and 5 had valvular cardiomyopathy). Out of 
them 4 (9%) were in NYHA I stage, 16 (36%) were in NYHA II 
stage, 18 (45%) were in NYHA III stage, and 7 (20%) were in 
NYHA IV stage. Fifty-five patients were diagnosed with solid 
hematological tumor (45 had diagnosis of non-Hodgkin lym-
phoma and 10 had diagnosis of Hodgkin disease). Forty-three 
had solid tumor of various sites (19 hepatocellular cancer, 8 colo-
rectal cancer, 8 pancreatic cancer, 3 billiary duct cancer, 2 gastric 
cancer, and 3 cancer of unknown primary site). Initial evaluation 
revealed that patients with chronic HF were significantly older 
(mean age 73.9 ± 10.5) than patients with solid tumors (mean 
age 62.9 ± 12.6; p = 0.0001), hematological diseases (mean age 
56.9 ± 14.6; p = 0.0001), and control group (mean age 65.1 ± 12.7; 
p = 0.007). We found no significant difference in the amount of 
weight loss, intensity of weight loss (kilograms/month), or preva-
lence of significant weight loss (defined as >5% loss in 12 months 
or less) between the disease groups.
TaBle 1 | Differences in anthropometric and laboratory variables, related 
to weight loss, between hF group and controls.
hF controls p-Value
Body weight (kg) 75.9 ± 15.4 84.4 ± 16.7 0.04*
Body mass index– (kg/m2) 26.5 ± 4.8 28.4 ± 8.0 0.04*
Grip strength (kg) 17.2 ± 9.7 26.8 ± 8.6 0.0005*
Mid-arm circumference (cm) 27.9 ± 3.7 30.4 ± 3.4 0.009*
Waist circumference (cm) 94.0 ± 11.2 100.0 ± 14.7 0.03*
Hip circumference (cm) 100.1 ± 8.8 100.4 ± 10.1 NS
Biceps skinfold (cm) 0.75 ± 0.44 1.0 ± 0.4 0.008*
Triceps skinfold (cm) 1.23 ± 0.50 1.48 ± 0.45 0.04*
Subscapular skinfold (cm) 1.43 ± 0.48 1.87 ± 0.5 0.002*
Suprailiac skinfold (cm) 1.28 ± 0.52 1.56 ± 0.51 0.04*
C-reactive protein (mg/L) 10.0 ± 11.6 4.3 ± 5.5 0.01*
Hemoglobin (g/dL) 13.3 ± 2.2 13.7 ± 1.4 NS
Albumin (g/dL) 3.8 ± 0.5 4.3 ± 0.4 0.0001*
Values are given as a mean ± SD.
*p < 0.05—Mann–Whitney U test.
HF, heart failure; NS, not significant.
TaBle 3 | Differences in anthropometric and laboratory variables, related 
to weight loss, between hF group and solid hematological tumor group.
hF solid hematological 
tumors
p-Value
Body weight (kg) 75.9 ± 15.4 80.7 ± 18.0 NS
Body mass index (kg/m2) 26.5 ± 4.8 27.5 ± 5.5 NS
Grip strength (kg) 17.2 ± 9.7 26.3 ± 10.2 0.0001*
Mid-arm circumference (cm) 27.9 ± 3.7 31.1 ± 4.1 0.0004*
Waist circumference (cm) 94.0 ± 11.2 96.3 ± 14.9 NS
Hip circumference (cm) 100.1 ± 8.8 102.9 ± 9.7 NS
Biceps skinfold (cm) 0.75 ± 0.44 0.84 ± 0.35 NS
Triceps skinfold (cm) 1.23 ± 0.50 1.35 ± 0.45 NS
Subscapular skinfold (cm) 1.43 ± 0.48 1.50 ± 0.59 NS
Suprailiac skinfold (cm) 1.28 ± 0.52 1.49 ± 0.59 NS
C-reactive protein (mg/L) 10.0 ± 11.6 15.9 ± 36.1 NS
Hemoglobin (g/dL) 13.3 ± 2.2 12.7 ± 2.3 NS
Albumin (g/dL) 3.8 ± 0.5 4.1 ± 0.6 0.0008*
Values are given as a mean ± SD.
*p < 0.05—Mann–Whitney U test.
HF, heart failure; NS, not significant.
TaBle 2 | Differences in anthropometric and laboratory variables, related 
to weight loss, between hF group and solid tumor group.
hF solid tumors p-Value
Body weight (kg) 75.9 ± 15.4 73.4 ± 16.9 NS
Body mass index (kg/m2) 26.5 ± 4.8 24.4 ± 4.7 0.04*
Grip strength (kg) 17.2 ± 9.7 24.7 ± 9.6 0.008*
Mid-arm circumference (cm) 27.9 ± 3.7 28.4 ± 4.2 NS
Waist circumference (cm) 94.0 ± 11.2 94.8 ± 12.6 NS
Hip circumference (cm) 100.1 ± 8.8 99.0 ± 10.0 NS
Biceps skinfold (cm) 0.75 ± 0.44 0.66 ± 0.29 NS
Triceps skinfold (cm) 1.23 ± 0.50 1.11 ± 0.46 NS
Subscapular skinfold (cm) 1.43 ± 0.48 1.24 ± 0.54 0.04*
Suprailiac skinfold (cm) 1.28 ± 0.52 1.18 ± 0.60 NS
C-reactive protein (mg/L) 10.0 ± 11.6 37.6 ± 43.5 0.0005*
Hemoglobin (g/dL) 13.3 ± 2.2 12.3 ± 1.9 0.02*
Albumin (g/dL) 3.8 ± 0.5 3.5 ± 0.7 NS
Values are given as a mean ± SD.
*p < 0.05—Mann–Whitney U test.
HF, heart failure; NS, not significant.
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anthropometric and laboratory 
Findings—chronic hF Patients vs. control 
Population
There was no significant difference in hip circumference in 
chronic HF patients compared to control population. All other 
anthropometric measurements were found to be significantly 
lower in chronic HF patients compared to controls.
Laboratory measurements revealed significantly higher levels 
of CRP (10.0 ± 11.6 vs. 4.3 ± 5.5 mg/L; p = 0.01) and lower levels 
of albumin (3.8 ± 0.5 vs. 4.4 ± 0.4 g/dL) in chronic HF patients 
compared to controls. Differences in anthropometric variables 
and laboratory parameters, related to weight loss, between HF 
group and controls are shown in Table 1.
anthropometric and laboratory 
Findings—chronic hF Patients vs. solid 
Tumors Patients
Chronic HF patients were found to have higher BMI (26.5 ± 4.8 vs. 
24.4 ±  4.7  kg/m2; p =  0.04) and higher measurements of sub-
scapular skinfold (1.43 ± 0.48, vs. 1.24 ± 0.54 cm; p = 0.04) when 
compared to patients in solid tumor group. On the other hand, 
HF patients were found to have lower muscle strength (17.2 ± 9.7 
vs. 24.7 ± 9.6 kg; p = 0.008). Laboratory findings revealed sig-
nificantly lower levels of CRP (10.0 ± 11.6 vs. 37.6 ± 47.5 mg/L; 
p =  0.0005) and higher levels of hemoglobin (13.3 ±  2.2 vs. 
12.3 ± 1.9 g/dL; p = 0.02) in chronic HF patients compared to 
solid tumor group. Differences in anthropometric variables and 
laboratory parameters, related to weight loss, between HF group 
and solid tumor group are given in Table 2.
anthropometric and laboratory 
Findings—chronic hF Patients vs. solid 
hematological Tumors Patients
When compared to patients with solid hematological tumors 
chronic HF patients were found to have lower muscle strength 
(17.2 ± 9.7 vs. 26.3 ± 10.2 kg; p = 0.0001) and mid-arm circum-
ference (27.9 ± 3.7 vs. 31.1 ± 4.1 cm; p = 0.0004). Laboratory data 
showed that HF patients had lower levels of albumin (3.8 ± 0.5 vs. 
4.1 ± 0.6 g/dL; p = 0.0008). Data for the two groups are shown 
in Table 3.
DiscUssiOn
Weight loss is an independent predictor of mortality both 
in patients with cancer as well as in patients with chronic HF 
(11–13). It is a powerful predictor of adverse events during cancer 
chemotherapy (4) and surgical procedures (3).
Mechanisms of weight loss in patients with cancer and chronic 
HF are regarded similar (14). Numerous studies have revealed 
excessive elaboration of pro-inflammatory cytokines both in 
tumor patients and patients with HF. Those cytokines are respon-
sible for exaggerated proteolysis and lipolysis as well as anorexia. 
All of these processes result in weight loss (1). Significant 
weight loss, called cachexia, is also a phenomenon observed in 
both HF and tumors as well as in some other chronic diseases. 
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This  advanced form of weight loss was also regarded as very 
similar in both conditions. Apparent similarity led to definitions 
of cachexia that were called generic, i.e., they could be applied 
to both patients with chronic HF and tumors (6). Yet, there was 
a general notion that a spectrum of metabolic and nutritional 
abnormalities of chronic diseases is wide and multifactorial 
in origin although some analogies exist (15). This notion led 
to newer, so called disease-specific definitions, of the cachexia 
syndrome. Cancer cachexia was the first nutritional disorder that 
was separately defined. New definition stated that it was designed 
for cancer patients and that the set criteria are cancer specific. 
It brought some other new concepts in studying the weight loss 
phenomenon most importantly the concept of staging of the 
weight loss (9). Concept of staging proved to have some benefits 
in subsequent clinical studies in cancer patients (16). This proof 
of some efficacy of new disease-specific definition and a general 
notion of multifactorial origin of weight loss in different diseases 
could not, in our opinion, substitute clinical studies. Such clini-
cal studies should show that there are indeed some differences in 
presentations of patients with weight loss and different diseases. 
Yet such studies, that prove disease-specific weight loss concept, 
are generally lacking.
Certain experimental data led some authors to claim that 
“weight loss alone does not identify the full effect of cachexia 
on physical function and is not a prognostic variable” (17). This 
was a cornerstone to new definitions of cachexia which stated 
that aside from weight loss patient needs to fulfill additional 
clinical and laboratory criteria to be diagnosed as cachectic (6, 9). 
Some of those additional criteria like reduced muscle strength 
or increased inflammatory response (18, 19) were found to be 
independent predictors of mortality.
The lack of studies comparing patients with different diseases 
related to weight loss as well as significant influence of some 
additional parameters on survival of such patients were principal 
reasons of our study (20). We tried to find any significant differ-
ences in relevant anthropometric and laboratory features, related 
to weight loss, in patients with chronic HF compared to patients 
with various tumors and controls. We gathered data from 143 
consecutive hospitalized patients with malignant diseases or 
chronic HF as well as data from 20 controls. Significant differ-
ences, both in anthropometric as well as laboratory features, in 
HF patients compared to control population were found. Those 
differences were not unexpected and were previously published 
(7). We then compared HF patients to patients with various tumor 
diseases. General notion of multifactorial nature of various can-
cers led us to further subdivide our tumor group. We decided to 
divide tumor patients into those with solid hematological tumors 
and those with solid tumors of any location. Initial analysis of 
amount of weight loss, intensity of weight loss, and prevalence of 
significant weight loss (>5% of weight in 12 months or less) found 
no differences between disease (i.e., HF vs. solid tumor vs. hema-
tological solid tumor) groups. Analysis of anthropometric data 
revealed that patients with solid tumors had had lower values of 
BMI and subscapular skinfold thickness as well as higher muscle 
strength compared to HF group. On the other hand, laboratory 
findings revealed that HF patients had lower levels of CRP and 
higher levels of hemoglobin compared to solid tumor group. 
Compared to solid hematological tumor group, HF patients had 
lower levels of albumin, lower muscle strength, as well as lower 
mid-arm circumference.
Observed differences are strongly in favor of a new concept 
that looks at weight loss as a disease-specific phenomenon (9). 
Our results are first to our knowledge that directly prove such con-
cept. They also imply different pathophysiological mechanisms 
of weight loss in patients with chronic HF compared to cancer 
patients. Although such mechanism are regarded as similar and 
probably rely mostly on excessive elaboration of pro-inflammatory 
cytokines found both in tumor patients and patients with HF (1), 
some differences have been found. Production of lipid mobilizing 
factor or proteolysis inducing factor was found exclusively in can-
cer patients (21) and could be a possible mechanisms responsible 
for the observed differences. There are also no studies that would 
compare profile and intensity of production of various inflamma-
tory cytokines in patients with HF or cancer. Unfortunately, our 
study did not explore pathophysiological differences but could 
serve as a cornerstone for future studies addressing this issue.
While analyzing our data, we found several possible problems 
that could have confounded the results. First, HF patients were 
significantly older than both tumor groups as well as control 
group. This difference in age could in fact be responsible for 
some differences observed. It is known that age can influence 
both some anthropometric (22) as well as some laboratory (23, 
24) measurements that were done in our study. One could say 
that observed strength reduction in HF patients could indeed 
be a reflection of age difference. On the other hand, some other 
observed differences, especially the ones in laboratory findings, 
cannot be explained by age differences. They are in fact quite 
opposite to what could be expected due to the age difference. 
Taking it all together, one can conclude that some part of our 
results could be influenced by age. On the other hand, most 
of the observed differences come probably from differences in 
pathophysiological mechanisms of various diseases included in 
our study and cannot be explained by age difference. Moreover, 
we believe that our results reflect clinical reality, i.e., the patients 
with HF are indeed older than tumor patients. If one is collecting 
data on consecutive patients, as we were, one should obtain the 
exact distribution of age as we did. To fully address the issue 
of age influence on our results, one should probably make an 
age-matched study. Our group is eagerly awaiting such results 
from other investigators.
Second possible problem could come from the fact that we 
collected data from hospitalized patients. This has given us a 
population of patients, especially in the solid tumor group, which 
does not reflect distribution of patients in general population. 
This specific distribution could have again influenced our results. 
Unfortunately, due to organizational/structural issues in our out-
patient clinic during the timeframe of our interest, we gathered 
all data from hospitalized patients. In that way, the distribution of 
patients in our study reflects the population of patients hospital-
ized in our institution. Again we await results of others that would 
address that issue.
One must also bear in mind, that using anthropometric vari-
ables, especially skinfolds, in a heterogeneous population as ours, 
is not well validated. Those variables are well validated in general 
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population and possible confounding could indeed exist. On the 
other hand, there have been no studies that have addressed this issue 
in systematical manner. Until such data are gathered, this confound-
ing of our study, although possible, remains purely speculative.
We would also like to stress that the choice to divide patients in 
two groups as described earlier, lies in the organizational issues, 
i.e., those are the patients who are hospitalized in our institution. 
Patients with other diseases associated with weight loss, such as 
patients with obstructive pulmonary disease or renal disease, are 
less frequently encountered in our institution. Tumor patients 
were further subdivided into ones with solid tumors and ones 
with solid hematological tumors. The reason for that lies in the 
fact that solid hematological tumors usually do not result in such 
a pronounced weight loss (25). On the other hand, hematological 
patients are usually not in the scope of the interest in the stud-
ies investigating weight loss. Taking all this together, especially 
taking into account relatively high proportion of our patients 
belonging to the hematological group, one could speculate that 
such large hematology group could confound our data. To avoid 
that, we choose to divide our tumor group in such way.
Taken it all together, we strongly believe that observed differ-
ences are indicative of differences in mechanisms of weight loss 
between patients with HF and tumor patients. Further studies 
are warranted to fully elucidate possible pathophysiological dif-
ferences and to address some possible pitfalls of our study. Till 
then, our results could serve as a cornerstone for future studies.
cOnclUsiOn
There are differences in some anthropometric and laboratory 
measurements, related to weight loss, between patients with HF 
and patients with various tumor diseases. Observed differences 
could imply different mechanisms of weight loss in those groups 
of patients. Further studies, especially ones addressing patho-
physiological mechanisms as well as addressing possible issues of 
our study, are warranted to confirm our findings.
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